Click here to close now.

Welcome!

News Feed Item

PURE Bioscience Reports Fiscal Third Quarter 2014 Financial Results

Early SDC Food Safety Revenue Led By QSR Commercial Market Test Rollout

SAN DIEGO, CA -- (Marketwired) -- 06/10/14 -- PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the second fiscal quarter ended April 30, 2014.

Fiscal Q3 Milestones
The Company reported that during the third fiscal quarter 2014, the new management team generated significant momentum in advancing its business strategy to commercialize its SDC-based technology as a food safety solution:

  • Extended commercial market test launch of PURE® Hard Surface Disinfectant to over 650 stores with a national brand QSR (quick service restaurant);
    • Positive customer field feedback on both SDC product performance and ease of use
    • Phased U.S. national rollout under development for expected system-wide launch
  • Rollout plans in development for wider plant adoption from five national food processors who placed commercial pilot orders;
    • Expanding SDC usage with enhanced hygiene and operating protocols
  • Reported outstanding initial test results for the application of SDC as a direct food contact processing aid for raw poultry;
    • Test results achieved undetectable levels of salmonella in raw poultry
      • Enhanced safety profile provides benefit to both plant environment and staff
    • Estimated potential addressable U.S. market opportunity for this new application exceeds $1 billion for poultry, produce and meats
    • Filing for required regulatory authorization from the FDA and USDA is expected later this month for poultry and Q3 2014 for produce and meats
    • Expected approval for U.S. commercial use by end of calendar 2014 for poultry

Summary of Results of Operations
Revenues for the third fiscal quarter of 2014 were $261,000, compared with revenues of $258,000 for the third fiscal quarter of 2013. Total operating costs and expenses, excluding share-based compensation, other share-based expenses, and restructuring costs, for the third fiscal quarter of 2014 and 2013, were $1.7 million, and $1.7 million, respectively. The net loss for the third fiscal quarter of 2014 was $(2.1) million, or $(0.07) per share, compared with a net loss of $(1.5) million, or $(0.14) per share, in the third fiscal quarter of 2013.

Revenues for the nine months ended April 30, 2014 were $417,000, compared with revenues of $631,000 for the nine months ended April 30, 2013. Total operating costs and expenses, excluding share-based compensation, other share-based expense, and restructuring costs, were $4.4 million, and $5.2 million, respectively, a reduction of 15%. The net loss for the nine months ended April 30, 2014 was $(8.4) million, or $(0.34) per share, compared with a net loss of $(5.5) million, or $(0.53) per share, in the nine months ended April 30, 2013. The adjusted net loss for the nine months ended April 30, 2014, as adjusted for significant items, was $(3.8) million compared with prior year adjusted net loss of $(4.9) million, a decrease of approximately a $1.1 million, or 22%.

As the Company continues to execute its new business strategy, it intends to:

  • Accelerate market penetration and revenue adoption of restaurant chains and food processors with SDC-based products
  • Leverage out-sourcing of its manufacturing operations
  • Out-license the SDC-technology platform to non-food markets
  • Secure additional capital to execute its business plan

Calendar 2014 Goals

  • Increase financial strength to accelerate strategy execution.
  • Secure customer adoption in food safety with 2+ national QSR chains and 5+ national food processors;
    a. Fiscal 4Q 2014 (July 31 2014): annual revenue run rate $3-$5M
    b. Fiscal 4Q 2015 (July 31 2015): positive EBITDA
  • Leverage outsourcing of operations and supply chain;
    a. Provide incremental cost savings and increase production scale
  • Secure FDA and USDA authorization for use of SDC as a direct food contact/processing aid;
    a. Initiate commercialization as a processing aid for poultry by end of calendar 2014
  • License PURE distribution and SDC applications to non-core markets.

Food Safety Solutions Provider
PURE's near-term business focus is to drive customer adoption of its products in the food industry. Its proprietary SDC-based products uniquely address food safety issues across the supply chain and help to prevent or mitigate food contamination and the potential for food-borne illness. The Company's target customers are foodservice operators, food processors and food manufacturers.

"This quarter operating results are in line with our expectations of completing the manufacturing technology transfer and initiating out-sourced production and distribution to our QSR market test and other customers," stated Peter C. Wulff, Chief Financial Officer and Chief Operating Officer. "We believe we are well positioned with our new operating structure to meet expected market demand."

Hank R. Lambert, Chief Executive Officer, said, "The recent progress we have made in extending the usage of PURE Hard Surface in QSRs and food processors, combined with compelling results generated by our testing of SDC as a processing aid for poultry, provide strong validation for our unique antimicrobial technology and give us great optimism for building revenue momentum in the coming months. We are increasingly confident that SDC will prove to be one of the most important advances in food safety in recent history."

Q3 Results Conference Call
The Company will host an investor conference call on Tuesday, June 10th, 2014 at 1:30pm PDT (4:30pm EDT).

The Participant Dial-In Number for the conference call is 1-412-902-6720. Participants should dial in to the call at least five minutes before 1:30pm PDT (4:30pm EDT) on June 10th, 2014. The call can also be accessed "live" or via replay online on the Company's website (http://www.purebio.com/about/investor_relations). The replay of the webcast will be available by dialing 1-877-870-5176 (international participants dial 1-858-384-5517) starting June 10th, 2014, at 7:30pm EDT through June 24th, 2014 at 11:59 pm EDT. Please use PIN Number 90610.

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing its proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control within the food industry. The Company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection. As a platform technology, SDC is distinguished from existing products in the marketplace by its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, including to manufacture its products, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.



                        Pure Bioscience, Inc.
           Condensed Consolidated Statements of Operations
                             (Unaudited)

                             Nine months ended        Three months ended
                                 April 30,                 April 30,
                         ------------------------  ------------------------
                             2014         2013         2014         2013
                         -----------  -----------  -----------  -----------

Net product sales        $   417,000  $   631,000  $   261,000  $   258,000

Operating costs and
 expenses
  Cost of goods sold         145,000      155,000       89,000       67,000
  Selling, general and
   administrative          3,506,000    4,093,000    1,338,000    1,332,000
  Research and
   development               750,000      979,000      248,000      283,000
  Share-based
   compensation            2,191,000      583,000      770,000      153,000
  Other share-based
   expenses                  308,000            -            -            -
  Restructuring costs      2,754,000            -            -            -
                         -----------  -----------  -----------  -----------
Total operating costs
 and expenses              9,654,000    5,810,000    2,445,000    1,835,000
                         -----------  -----------  -----------  -----------

Loss from operations      (9,237,000)  (5,179,000)  (2,184,000)  (1,577,000)

Other income (expense)
  Change in derivative
   liability                 (56,000)     270,000        3,000       30,000
  Interest expense, net       (7,000)    (591,000)      (2,000)      (2,000)
  Gain on extinguishment
   of debt                   727,000            -            -            -
  Other income
   (expense), net            198,000      (12,000)     134,000       15,000
                         -----------  -----------  -----------  -----------
Total other income
 (expense)                   862,000     (333,000)     135,000       43,000
                         -----------  -----------  -----------  -----------

Net loss                 $(8,375,000) $(5,512,000) $(2,049,000) $(1,534,000)
                         ===========  ===========  ===========  ===========

Basic and diluted net
 loss per share          $     (0.34) $     (0.53) $     (0.07) $     (0.14)
                         ===========  ===========  ===========  ===========

Shares used in computing
 basic and diluted net
 loss per share           24,479,959   10,310,721   27,864,746   11,255,833
                         ===========  ===========  ===========  ===========



                           Pure Bioscience, Inc.
                   Condensed Consolidated Balance Sheets

                                                 April 30,       July 31,
                                                    2014           2013
                                               -------------  -------------
                                                (Unaudited)
Assets
Current assets
  Cash and cash equivalents                    $     416,000  $      32,000
  Accounts receivable, net                            34,000         18,000
  Inventories, net                                   387,000        365,000
  Prepaid expenses                                   194,000         71,000
                                               -------------  -------------
  Total current assets                             1,031,000        486,000

Property, plant and equipment, net                    42,000        146,000
Patents, net                                       1,378,000      1,430,000
                                               -------------  -------------

Total assets                                   $   2,451,000  $   2,062,000
                                               =============  =============

Liabilities and stockholders' equity (deficit)
Current liabilities
  Accounts payable                             $     529,000  $   1,134,000
  Restructuring liability                            512,000              -
  Note payable, current                                    -        368,000
  Accrued liabilities                                105,000        600,000
  Derivative liability                                10,000         51,000
                                               -------------  -------------
  Total current liabilities                        1,156,000      2,153,000

Note payable, less current portion                         -        887,000
Deferred rent                                              -         13,000
                                               -------------  -------------
Total liabilities                                  1,156,000      3,053,000
                                               -------------  -------------

Commitments and contingencies

Stockholders' equity (deficit)
  Preferred stock, $0.01 par value: 5,000,000
   shares authorized, no shares issued                     -              -
  Common stock, $0.01 par value: 100,000,000
   shares authorized, 28,555,500 shares issued
   and outstanding at April 30, 2014, and
   12,569,503 shares issued and outstanding at
   July 31, 2013                                     286,000        126,000
  Additional paid-in capital                      79,555,000     69,054,000
  Accumulated deficit                            (78,546,000)   (70,171,000)
                                               -------------  -------------
Total stockholders' equity (deficit)               1,295,000       (991,000)
                                               -------------  -------------

Total liabilities and stockholders' equity
 (deficit)                                     $   2,451,000  $   2,062,000
                                               =============  =============



                           Pure Bioscience, Inc.
               Reconciliation of Non-GAAP Financial Measures
                                (Unaudited)

                             Nine months ended        Three months ended
                                 April 30,                 April 30,
                         ------------------------  ------------------------
                             2014         2013         2014         2013
                         -----------  -----------  -----------  -----------

Net loss, as reported    $(8,375,000) $(5,512,000) $(2,049,000) $(1,534,000)

Add back significant
 items:
  Share-based
   compensation            2,191,000      583,000      770,000      153,000
  Other share-based
   expenses                  308,000            -            -            -
  Restructuring costs      2,754,000            -            -            -
  Gain on extinguishment
   of debt                  (727,000)                        -            -
                         -----------  -----------  -----------  -----------
Net loss, as adjusted
 for significant items   $(3,849,000) $(4,929,000) $(1,279,000) $(1,381,000)
                         -----------  -----------  -----------  -----------



Contacts:
Tom Hemingway
Redwood Investment Group
714-978-4425
Email Contact

Terri MacInnis
VP of IR
Bibicoff + MacInnis, Inc.
818-379-8500
Email Contact

Company Contact:
Peter C. Wulff
CFO & COO
PURE Bioscience, Inc.
619-596-8600 ext.111
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Even as cloud and managed services grow increasingly central to business strategy and performance, challenges remain. The biggest sticking point for companies seeking to capitalize on the cloud is data security. Keeping data safe is an issue in any computing environment, and it has been a focus since the earliest days of the cloud revolution. Understandably so: a lot can go wrong when you allow valuable information to live outside the firewall. Recent revelations about government snooping, along...
Public Cloud IaaS started its life in the developer and startup communities and has grown rapidly to a $20B+ industry, but it still pales in comparison to how much is spent worldwide on IT: $3.6 trillion. In fact, there are 8.6 million data centers worldwide, the reality is many small and medium sized business have server closets and colocation footprints filled with servers and storage gear. While on-premise environment virtualization may have peaked at 75%, the Public Cloud has lagged in adop...
"We have an new division call the Cloud Monetization Division, based on our platform Powua, which empowers enterprises and organizations to take the journey to cloud monetization and to make it a reality," explained Ian Khan, Manager, Innovation & Marketing at Solgenia, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
In the midst of the widespread popularity and adoption of cloud computing, it seems like everything is being offered “as a Service” these days: Infrastructure? Check. Platform? You bet. Software? Absolutely. Toaster? It’s only a matter of time. With service providers positioning vastly differing offerings under a generic “cloud” umbrella, it’s all too easy to get confused about what’s actually being offered. In his session at 16th Cloud Expo, Kevin Hazard, Director of Digital Content for SoftL...
DevOps Summit, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development...
The last decade was about virtual machines, but the next one is about containers. Containers enable a service to run on any host at any time. Traditional tools are starting to show cracks because they were not designed for this level of application portability. Now is the time to look at new ways to deploy and manage applications at scale. In his session at @DevOpsSummit, Brian “Redbeard” Harrington, a principal architect at CoreOS, will examine how CoreOS helps teams run in production. Attende...
Agile, which started in the development organization, has gradually expanded into other areas downstream - namely IT and Operations. Teams – then teams of teams – have streamlined processes, improved feedback loops and driven a much faster pace into IT departments which have had profound effects on the entire organization. In his session at DevOps Summit, Anders Wallgren, Chief Technology Officer of Electric Cloud, will discuss how DevOps and Continuous Delivery have emerged to help connect dev...
"AgilData is the next generation of dbShards. It just adds a whole bunch more functionality to improve the developer experience," noted Dan Lynn, CEO of AgilData, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
To many people, IoT is a buzzword whose value is not understood. Many people think IoT is all about wearables and home automation. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed some incredible game-changing use cases and how they are transforming industries like agriculture, manufacturing, health care, and smart cities. He will discuss cool technologies like smart dust, robotics, smart labels, and much more. Prepare...
In their general session at 16th Cloud Expo, Michael Piccininni, Global Account Manager - Cloud SP at EMC Corporation, and Mike Dietze, Regional Director at Windstream Hosted Solutions, reviewed next generation cloud services, including the Windstream-EMC Tier Storage solutions, and discussed how to increase efficiencies, improve service delivery and enhance corporate cloud solution development. Michael Piccininni is Global Account Manager – Cloud SP at EMC Corporation. He has been engaged in t...
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides private all-in-one social intranets allowing workers to securely collaborate from anywhere in the world and from any device. Social, mobile, and easy to use. MangoApps has been named a "Market Leader" by Ovum Research and a "Cool Vendor" by Gartner. 20,000+ business custome...
SYS-CON Events announced today that Alert Logic, the leading provider of Security-as-a-Service solutions for the cloud, has been named “Bronze Sponsor” of SYS-CON's 17th International Cloud Expo® and DevOps Summit 2015 Silicon Valley, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Alert Logic provides Security-as-a-Service for on-premises, cloud, and hybrid IT infrastructures, delivering deep security insight and continuous protection for cust...
The cloud has transformed how we think about software quality. Instead of preventing failures, we must focus on automatic recovery from failure. In other words, resilience trumps traditional quality measures. Continuous delivery models further squeeze traditional notions of quality. Remember the venerable project management Iron Triangle? Among time, scope, and cost, you can only fix two or quality will suffer. Only in today's DevOps world, continuous testing, integration, and deployment upend...
SYS-CON Media announced today that CloudBees, the Jenkins Enterprise company, has launched ad campaigns on SYS-CON's DevOps Journal. CloudBees' campaigns focus on the business value of Continuous Delivery and how it has been recognized as a game changer for IT and is now a top priority for organizations, and the best ways to optimize Jenkins to ensure your continuous integration environment is optimally configured.
SYS-CON Events announced today that Solgenia will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Solgenia is the global market leader in Cloud Collaboration and Cloud Infrastructure software solutions. Designed to “Bridge the Gap” between Personal and Professional Social, Mobile and Cloud user experiences, our solutions help large and medium-sized organizations dramatically improve produc...